Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Curr Alzheimer Res ; 9(8): 913-23, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22299617

RESUMEN

It has been hypothesized that pro-inflammatory cytokines may play a pathogenic role in Alzheimer's disease (AD), and that n-3 polyunsaturated fatty acids may be protective against the development and progression of this disease. A reduced release of inflammatory cytokines by lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs) from AD patients dietary supplemented with a mixture of eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) was recently reported. On this basis, we investigated the possible differential effects of the two purified fatty acids on inflammatory cytokine release, a subject still not explored, even though of great pharmacological interest. We treated in vitro phytohaemagglutinin (PHA)- or LPS-stimulated PBMCs from AD patients and age-matched healthy controls (HCs) with purified EPA or DHA. Higher pro- to anti-inflammatory cytokine ratios, indicative of a pro-inflammatory profile, were observed in PHA-stimulated PBMCs from AD patients in basal conditions. The addition of both EPA and DHA markedly reduced the cytokine release, with DHA showing always a more prominent effect than EPA. However, whereas DHA reduced only the high IL-1ß/IL-10 ratio, EPA was able to reduce also the IL-6/IL-10 ratio. In stimulated PMBCs from HCs the reducing effect on cytokine release was not always observed, or observed at a lower degree. In conclusion, whereas DHA appeared more powerful in inhibiting each single inflammatory cytokine, the proinflammatory profile of the AD patients' cells was better reverted by EPA to a profile more similar to that found in HCs. A combination of both the fatty acids, seems to be still the best solution.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Citocinas/metabolismo , Ácidos Docosahexaenoicos/farmacología , Ácido Eicosapentaenoico/farmacología , Leucocitos Mononucleares/efectos de los fármacos , Anciano , Enfermedad de Alzheimer/inmunología , Células Cultivadas , Femenino , Humanos , Inflamación/inmunología , Inflamación/metabolismo , Leucocitos Mononucleares/metabolismo , Masculino
2.
Chem Res Toxicol ; 24(12): 2093-105, 2011 Dec 19.
Artículo en Inglés | MEDLINE | ID: mdl-21902224

RESUMEN

There is some evidence to support the toxicity of polyunsaturated fatty acids (PUFAs) and their oxidative products, suggesting their involvement in the pathogenesis of different chronic diseases, including cancer. It has been shown that products of PUFA oxidation may exert a carcinogenic action by forming mutagenic adducts with DNA. However, a large amount of evidence accumulated over several decades has indicated the beneficial effects of administration of n-3 PUFAs in the prevention and therapy of a series of diseases. In particular, there is much evidence that n-3 PUFAs exert anti-inflammatory and antineoplastic effects, whereas n-6 PUFAs promote inflammation and carcinogenesis. In our tissues, both of the two classes of PUFAs can be converted into bioactive products, incorporated into membrane phospholipids or bound to membrane receptors, where they may alter, often in opposite ways, transduction pathways and affect important biological processes, such as cell death and survival, inflammation, and neo-angiogenesis. In the present review, we intend to shed light on the paradox of the coexisting healthy and toxic effects of n-3 PUFAs, focusing on their possible pro-oxidant cytotoxic and carcinogenic effect, in order to understand if their increased intake, recommended by a number of health agencies worldwide and promoted by nutraceutical producers, may or may not represent a hazard to human health.


Asunto(s)
Suplementos Dietéticos/toxicidad , Ácidos Grasos Insaturados/toxicidad , Antioxidantes/farmacología , Ácidos Grasos Omega-3/síntesis química , Ácidos Grasos Omega-3/farmacología , Ácidos Grasos Omega-3/toxicidad , Ácidos Grasos Omega-6/síntesis química , Ácidos Grasos Omega-6/farmacología , Ácidos Grasos Omega-6/toxicidad , Ácidos Grasos Insaturados/química , Ácidos Grasos Insaturados/farmacología , Humanos , Oxidación-Reducción/efectos de los fármacos
3.
Recenti Prog Med ; 101(10): 389-92, 2010 Oct.
Artículo en Italiano | MEDLINE | ID: mdl-21137574

RESUMEN

Dispepsy is one of the most diffuse syndromes in general population. The high number of subjects affected from this pathology and the very annoying symptomatology does so as that the pharmaceutical costs of antacids and of prokinetics are very high. Aim of the study is to assess if a hydropinic therapy is able to facilitate digestive processes of the dispeptic patients accelerating gastric emptying. The 30 recruited subjects, 20 patients and 10 healthy volunteers, have answered to test about their symptoms and have executed a 13C octanoic acid breath test in order to estimate the gastric emptying to a basal time, and 30 days after supplementation of mineral water, 1.5 liters/day, for 21 days. At the end of the study, both the time of gastric emptying and the gastrointestinal symptoms improved after the hydropinic therapy, demonstrating that a supplementazione with mineral water can induce a benefit in the dispeptics subjects.


Asunto(s)
Dispepsia/fisiopatología , Dispepsia/terapia , Vaciamiento Gástrico , Aguas Minerales/uso terapéutico , Dispepsia/complicaciones , Femenino , Enfermedades Gastrointestinales/etiología , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA